← Back to patent-cliff list
CAS 108-59-8
dimethyl malonate1,3-Dimethyl propanedioate
Codes: BRIV-021, NINT-014, PRAL-020, RETAG-002, RISD-012, PEME-033, Urapidil-018
Application context (from source-drug indications)
Partial-onset seizureBrivaracetamEpilepsyBrivaracetamSeizureBrivaracetamSystemic sclerosis-associated interstitial lung diseaseNintedanib EsylateIdiopathic pulmonary fibrosisNintedanib EsylateNon-small cell lung cancerNintedanib EsylatePulmonary fibrosisNintedanib EsylateInterstitial lung diseaseNintedanib EsylateHereditary haemorrhagic telangiectasiaNintedanib EsylatePeripheral T-cell lymphomaPralatrexateT-cell lymphomaPralatrexateSolid tumourPralatrexateHaematological malignancyPralatrexateB-cell lymphomaPralatrexateCutaneous T-cell lymphomaPralatrexateType 2 diabetesRetagliptin PhosphateDiabetesRetagliptin PhosphateRenal impairmentRetagliptin PhosphateSpinal muscular atrophyRisdiplamNon-small cell lung cancerPemetrexed Disodium Hydrate间皮组织肿瘤Pemetrexed Disodium Hydrate胸膜孤立性纤维瘤Pemetrexed Disodium HydrateBladder cancerPemetrexed Disodium HydrateUrothelial carcinomaPemetrexed Disodium HydrateSolid tumourPemetrexed Disodium HydrateHypertensionUrapidil hydrochloride
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Brivaracetam | Tier C — Watch / trade | 2028 |
| Nintedanib Esylate | Tier B — Position early | - |
| Pralatrexate | Tier C — Watch / trade | - |
| Retagliptin Phosphate | Tier C — Watch / trade | - |
| Risdiplam | Tier B — Position early | - |
| Pemetrexed Disodium Hydrate | Tier B — Position early | - |
| Urapidil hydrochloride | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(S)-2-aminobutanamide→(S)-2-((R)-2-oxo-4-propylpyrrolidin-1-yl)butanamide→pent-1-ene→(R)-pentane-1,2-diol→(4R)-4-propyl-1,3,2-dioxathiolane 2-oxide→(R)-4-propyl-1,3,2-dioxathiolane 2,2-dioxide→dimethyl malonate→(R)-dimethyl 2-propylcyclopropane-1,1-dicarboxylate→(R)-2-propylcyclopropane-1,1-dicarboxylic acid→(R)-6,6-dimethyl-1-propyl-5,7-dioxaspiro[2.5]octane-4,8-dione→(4R)-1-((S)-1-amino-1-oxobutan-2-yl)-2-oxo-4-propylpyrrolidine-3-carboxylic acid→1-((S)-1-amino-1-oxobutan-2-yl)-2-oxo-5-propylpyrrolidine-3-carboxylic acid→(4R)-methyl 1-((S)-1-amino-1-oxobutan-2-yl)-2-oxo-4-propylpyrrolidine-3-carboxylate→methyl 1-((S)-1-amino-1-oxobutan-2-yl)-2-oxo-5-propylpyrrolidine-3-carboxylate→(2S)-2-(2-oxo-5-propylpyrrolidin-1-yl)butanamide
methyl 2-oxo-1,3-dihydroindole-6-carboxylate →(trimethoxymethyl)benzene→N-(4-aminophenyl)-2-(4-methylpiperazin-1-yl)acetamide→1-methylpiperazine→4-chloro-3-nitrobenzoic acid→methyl 4-chloro-3-nitrobenzoate→dimethyl malonate→dimethyl 2-(4-(methoxycarbonyl)-2-nitrophenyl)malonate→2-chloroacetic anhydride→methyl 1-(2-chloroacetyl)-2-oxoindoline-6-carboxylate→(Z)-methyl 1-(2-chloroacetyl)-3-(methoxy(phenyl)methylene)-2-oxoindoline-6-carboxylate→(Z)-methyl 3-(methoxy(phenyl)methylene)-2-oxoindoline-6-carboxylate→ethanesulfonic acid→N-methyl-4-nitroaniline→2-chloroacetyl chloride→2-chloro-N-methyl-N-(4-nitrophenyl)acetamide
methyl 4-formylbenzoate→methyl 4-(8-methoxy-6,8-dioxooct-1-yn-4-yl)benzoate→methyl (E)-4-(3-oxobut-1-en-1-yl)benzoate→dimethyl malonate→sodium 2,4'-bis(methoxycarbonyl)-5-oxo-1,2,5,6-tetrahydro-[1,1'-biphenyl]-3-olate→5'-hydroxy-3'-oxo-1',2',3',6'-tetrahydro-[1,1'-biphenyl]-4-carboxylic acid→methyl 5'-methoxy-3'-oxo-1',2',3',6'-tetrahydro-[1,1'-biphenyl]-4-carboxylate→methyl 5'-chloro-3'-oxo-1',2',3',6'-tetrahydro-[1,1'-biphenyl]-4-carboxylate→sodium (Z)-4-methoxy-4-oxobut-2-en-2-olate→methyl 5'-(2-methoxy-2-oxoethyl)-3'-oxo-1',2',3',6'-tetrahydro-[1,1'-biphenyl]-4-carboxylate→4-nitrobenzenesulfonohydrazide
2-(2,4,5-trifluorophenyl)acetic acid→dimethyl malonate→methyl 3-oxo-4-(2,4,5-trifluorophenyl)butanoate→(S)-2-amino-2-phenylethanol→(S,E)-methyl 3-((2-hydroxy-1-phenylethyl)amino)-4-(2,4,5-trifluorophenyl)but-2-enoate→(S)-3-phenyl-5-(2,4,5-trifluorobenzyl)-3,4-dihydro-1,4-oxazepin-7(2H)-one→(3S,5R)-3-phenyl-5-(2,4,5-trifluorobenzyl)-1,4-oxazepan-7-one→methyl 3-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine-1-carboxylate→methyl 7-((R)-3-(((S)-2-hydroxy-1-phenylethyl)amino)-4-(2,4,5-trifluorophenyl)butanoyl)-3-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine-1-carboxylate→methyl 2-amino-2-(pyrazin-2-yl)acetate hydrochloride→2,2,2-trifluoroacetic anhydride→methyl 2-(pyrazin-2-yl)-2-(2,2,2-trifluoroacetamido)acetate→methyl 3-(trifluoromethyl)imidazo[1,5-a]pyrazine-1-carboxylate
3,6-dichloro-4-methylpyridazine→6-chloro-5-methylpyridazin-3-amine→6-chloro-4-methylpyridazin-3-amine→1-bromo-2,2-dimethoxypropane→6-chloro-2,8-dimethylimidazo[1,2-b]pyridazine→4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane)→2,8-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-b]pyridazine→2-chloro-7-fluoro-4H-pyrido[1,2-a]pyrimidin-4-one→2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-fluoro-4H-pyrido[1,2-a]pyrimidin-4-one→4,7-diazaspiro[2.5]octane hydrogen chloride→5-fluoropyridin-2-amine→dimethyl malonate→7-fluoro-2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one
guanidine→1-phenylethan-1-amine→methyl carbonochloridate→methyl (1-phenylethyl)carbamate→(E)-1-bromobut-2-ene→methyl (E)-but-2-en-1-yl(1-phenylethyl)carbamate→(E)-N-(1-phenylethyl)but-2-en-1-amine→dimethyl malonate→methyl (E)-3-(but-2-en-1-yl(1-phenylethyl)amino)-3-oxopropanoate→methyl 2-oxo-1-(1-phenylethyl)-4-vinylpyrrolidine-3-carboxylate→methyl 1-(1-phenylethyl)-2-thioxo-4-vinylpyrrolidine-3-carboxylate→2-amino-7-(1-phenylethyl)-5-vinyl-3,5,6,7-tetrahydro-4H-pyrrolo[2,3-d]pyrimidin-4-one→diethyl (4-iodobenzoyl)-L-glutamate→diethyl (4-(2-(2-amino-4-oxo-7-(1-phenylethyl)-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzoyl)-L-glutamate
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Unibest Taizhou GMP-like Site | Brivaracetam Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | (+)-(R)-4-propyl-4,5-dihydrofuran-2(3H)-one Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 2-Chloro-N-methyl-N-(4-nitrophenyl)acetamide Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | Trimethyl orthobenzoate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | N-(4-Aminophenyl)-N-methyl-2-(4-methylpiperazin -1-yl)acetamide Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | Methyl 2-oxoindole-6-carboxylate Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | (3E)-2,3-Dihydro-3-(methoxyphenylmethylene) -2-oxo-1H-indole-6- carboxylic acid methyl ester Pharmaceutical Intermediates | On request | On request | On request | — | |
| Qualified Partner — East China API Works | 7-fluoro-2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Nantong cGMP Site | 4-Boc-4,7-diazaspiro[2.5]octane Pharmaceutical Intermediates | On request | On request | On request | — | |
| Unibest Taizhou GMP-like Site | 2,8-Dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-b]pyridazine Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.